381 related articles for article (PubMed ID: 24736453)
21. Neuronal Presentation of Antigen and Its Possible Role in Parkinson's Disease.
Hobson BD; Sulzer D
J Parkinsons Dis; 2022; 12(s1):S137-S147. PubMed ID: 35253783
[TBL] [Abstract][Full Text] [Related]
22. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin.
D'Amato RJ; Lipman ZP; Snyder SH
Science; 1986 Feb; 231(4741):987-9. PubMed ID: 3080808
[TBL] [Abstract][Full Text] [Related]
23. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
[TBL] [Abstract][Full Text] [Related]
24. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.
Burbulla LF; Song P; Mazzulli JR; Zampese E; Wong YC; Jeon S; Santos DP; Blanz J; Obermaier CD; Strojny C; Savas JN; Kiskinis E; Zhuang X; Krüger R; Surmeier DJ; Krainc D
Science; 2017 Sep; 357(6357):1255-1261. PubMed ID: 28882997
[TBL] [Abstract][Full Text] [Related]
25. Pathological dynamics of activated microglia following medial forebrain bundle transection.
Cho BP; Song DY; Sugama S; Shin DH; Shimizu Y; Kim SS; Kim YS; Joh TH
Glia; 2006 Jan; 53(1):92-102. PubMed ID: 16206155
[TBL] [Abstract][Full Text] [Related]
26. Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein.
Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
Parkinsonism Relat Disord; 2019 Jul; 64():194-201. PubMed ID: 31000327
[TBL] [Abstract][Full Text] [Related]
27. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.
Gründemann J; Schlaudraff F; Haeckel O; Liss B
Nucleic Acids Res; 2008 Apr; 36(7):e38. PubMed ID: 18332041
[TBL] [Abstract][Full Text] [Related]
28. The new line of genetically modified mice with constitutive knockout of the gene alpha synuclein to study pathogenetic aspects of differential loss of dopaminergic neurons .
Tarasova TV; Ustyugov AA; Ninkina NN; Skvortsova VI
Patol Fiziol Eksp Ter; 2016; 60(3):4-9. PubMed ID: 29243900
[TBL] [Abstract][Full Text] [Related]
29. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
Kim HD; Jeong KH; Jung UJ; Kim SR
J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
[TBL] [Abstract][Full Text] [Related]
30. Immunoproteasome is up-regulated in rotenone-induced Parkinson's disease rat model.
Sun C; Jia G; Wang X; Wang Y; Liu Y
Neurosci Lett; 2020 Nov; 738():135360. PubMed ID: 32905834
[TBL] [Abstract][Full Text] [Related]
31. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.
Simunovic F; Yi M; Wang Y; Macey L; Brown LT; Krichevsky AM; Andersen SL; Stephens RM; Benes FM; Sonntag KC
Brain; 2009 Jul; 132(Pt 7):1795-809. PubMed ID: 19052140
[TBL] [Abstract][Full Text] [Related]
33. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
Duda J; Pötschke C; Liss B
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
[TBL] [Abstract][Full Text] [Related]
34. Ferritin and neuromelanin "quantum dot" array structures in dopamine neurons of the substantia nigra pars compacta and norepinephrine neurons of the locus coeruleus.
Rourk CJ
Biosystems; 2018 Sep; 171():48-58. PubMed ID: 30048795
[TBL] [Abstract][Full Text] [Related]
35. Neuromelanin of the human substantia nigra: an update.
Zucca FA; Basso E; Cupaioli FA; Ferrari E; Sulzer D; Casella L; Zecca L
Neurotox Res; 2014 Jan; 25(1):13-23. PubMed ID: 24155156
[TBL] [Abstract][Full Text] [Related]
36. Complex network-driven view of genomic mechanisms underlying Parkinson's disease: analyses in dorsal motor vagal nucleus, locus coeruleus, and substantia nigra.
Corradini BR; Iamashita P; Tampellini E; Farfel JM; Grinberg LT; Moreira-Filho CA
Biomed Res Int; 2014; 2014():543673. PubMed ID: 25525598
[TBL] [Abstract][Full Text] [Related]
37. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
38. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease.
Tripathy D; Chakraborty J; Mohanakumar KP
Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946
[TBL] [Abstract][Full Text] [Related]
39. A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules.
Wang S; Han QW; Zhou TT; Zhang CL; Zhu CG; Zhou X; Chen NH; Yuan YH; Shi JG
Int Immunopharmacol; 2021 Feb; 91():107269. PubMed ID: 33340781
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
